Deep Track Capital, LP
Q3 2023 13F-HR Holdings
Net value change ($000)
+430,562
(19.9%)
New positions
16
Sold out positions
7
Turnover %
14.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2023
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| GH | 66,342 | 123.5% |
| AXSM | 52,118 | 188.8% |
| APGE | 51,426 | NEW |
| NVCR | 40,375 | NEW |
| HilleVax, Inc. | 39,005 | NEW |
| Intra-Cellular Therapies, Inc. | 37,399 | 38.1% |
| NBIX | 33,750 | NEW |
| PACB | 30,799 | 159.6% |
| NTLA | 29,171 | 85.6% |
| EDIT | 26,971 | 94.9% |
Top Reduces (Value $000, Stocks/ETFs)
| TVTX | -47,315 | -41.8% |
| GERN | -23,105 | -29.8% |
| BEAM | -17,636 | -41.9% |
| VRNA | -15,427 | -22.9% |
| FDMT | -14,835 | -29.6% |
| GPCR | -13,473 | -12.2% |
| AGEN | -12,182 | -25.4% |
| SpringWorks Therapeutics, Inc. | -10,994 | -11.8% |
| Orchard Therapeutics plc | -10,637 | -100.0% |
| INOZYME PHARMA INC | -9,157 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
12,063
(0.5% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|